Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shutdown Week Two: Could Sponsors Find A More Focused FDA?

Executive Summary

User-fee supported employees continue to work on pending reviews, and the lack of distractions from other tasks may help sponsors as the shutdown continues.

You may also be interested in...



As US FDA Shutdown Continues, What Will Be The Cost Of Not Spending?

Bolus of applications could be filed once government reopens, but employee morale and recruitment efforts could suffer drop-off.

As US FDA Shutdown Continues, What Will Be The Cost Of Not Spending?

Bolus of applications could be filed once government reopens, but employee morale and recruitment efforts could suffer drop-off.

US FDA Enters Shutdown Mode: Reviews Will Continue, But Will Morale?

User fee funding will allow many functions to continue, but only 58% of staff will be retained until funding deal is reached.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS055674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel